volagidemab

沃拉德单抗

Report date: 2026/05/09 20:00:18

Base Information

Drug Namevolagidemab
Drug Alias NameAMG-477REMD-477
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGlucagon receptor antagonists
TargetsGlucagon receptor
Therapy Area/IndicationsIron deficiencyInsulin ResistanceHyperglycemia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesUT Health San AntonioRemd Biotherapeutics IncUniversity Of California San Diego +[4] 
Inactive CompaniesDuke University
Active IndicationsIron deficiencyInsulin ResistanceDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsHyperglycemiaDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A